Shilpa Medicare Limited (IN:SHILPAMED)
:SHILPAMED
SHILPAMED Stock Chart & Stats
₹319.90
-₹8.10(-0.96%)
At close: 4:00 PM EST
₹319.90
-₹8.10(-0.96%)
Day’s Range― - ―
52-Week Range₹260.00 - ₹501.60
Previous CloseN/A
Volume218.26K
Average Volume (3M)38.83K
Market Cap
₹81.98B
Enterprise Value₹87.70B
Total Cash (Recent Filing)₹535.50M
Total Debt (Recent Filing)₹5.93B
Price to Earnings (P/E)35.2
Beta0.91
Next Earnings
May 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.16%
Share Statistics
EPS (TTM)2.28
Shares Outstanding195,581,820
10 Day Avg. Volume85,780
30 Day Avg. Volume38,829
Financial Highlights & Ratios
PEG Ratio0.69
Price to Book (P/B)2.70
Price to Sales (P/S)4.98
P/FCF Ratio-57.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)22.1
Revenue Forecast (FY)₹17.05B
Bulls Say, Bears Say
Bulls Say
High Gross MarginsA 68% gross margin reflects strong pricing power and product differentiation from complex oncology APIs/formulations. Durable gross margins provide cushion against input cost swings, support reinvestment in R&D and capacity, and underpin long-term profitability even if operating costs rise.
Low Leverage, Strong Equity BaseSignificantly lower leverage and a high equity ratio mean the company has durable financial flexibility to fund capex, regulatory filings and capacity expansion without heavy refinancing. This reduces solvency risk and helps sustain long-term investment in specialty capabilities.
Specialization In Oncology And Regulated MarketsA strategic focus on complex oncology products and regulated markets creates high technical and regulatory barriers to entry, enabling long-term customer stickiness, premium pricing and recurring CDMO/complex supply contracts that support sustainable revenue and margin profiles.
Bears Say
Falling Operating MarginsA large decline in EBIT margin signals weakening operating efficiency or adverse product-mix shifts. If persistent, lower operating leverage will erode the conversion of strong gross profits into operating cash and reduce available funds for R&D, capacity or shareholder returns.
Negative Free Cash Flow From Heavy CapexSustained negative free cash flow driven by elevated capex strains liquidity and may force external financing or slower paydown of liabilities. While capex can build future capacity, near-term cash conversion weakness limits flexibility for dividends, debt reduction, or opportunistic investments.
Moderate Net Returns And ROEDespite revenue growth, modest net margins and a low ROE indicate limited returns on invested capital. Over the medium term this constrains the firm's ability to generate shareholder value from reinvested earnings unless margins or capital efficiency materially improve.
Shilpa Medicare Limited News
SHILPAMED FAQ
What was Shilpa Medicare Limited’s price range in the past 12 months?
Shilpa Medicare Limited lowest stock price was ₹260.00 and its highest was ₹501.60 in the past 12 months.
What is Shilpa Medicare Limited’s market cap?
Shilpa Medicare Limited’s market cap is ₹81.98B.
When is Shilpa Medicare Limited’s upcoming earnings report date?
Shilpa Medicare Limited’s upcoming earnings report date is May 21, 2026 which is in 41 days.
How were Shilpa Medicare Limited’s earnings last quarter?
Shilpa Medicare Limited released its earnings results on Feb 06, 2026. The company reported ₹2.28 earnings per share for the quarter, missing the consensus estimate of ₹2.8 by -₹0.52.
Is Shilpa Medicare Limited overvalued?
According to Wall Street analysts Shilpa Medicare Limited’s price is currently Overvalued.
Does Shilpa Medicare Limited pay dividends?
Shilpa Medicare Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.16%. See more information on Shilpa Medicare Limited dividends here
What is Shilpa Medicare Limited’s EPS estimate?
Shilpa Medicare Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shilpa Medicare Limited have?
Shilpa Medicare Limited has 195,581,820 shares outstanding.
What happened to Shilpa Medicare Limited’s price movement after its last earnings report?
Shilpa Medicare Limited reported an EPS of ₹2.28 in its last earnings report, missing expectations of ₹2.8. Following the earnings report the stock price went down -0.663%.
Which hedge fund is a major shareholder of Shilpa Medicare Limited?
Currently, no hedge funds are holding shares in IN:SHILPAMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Shilpa Medicare Limited
Shilpa Medicare Limited, together with its subsidiaries, engages in the manufacturing and selling active pharmaceutical ingredients (API's), intermediates, and formulations in India, the United States, Europe, and internationally. It offers oncology and non-oncology API's.; and new drug delivery systems, peptides/biotech products, specialty chemicals, etc. The company also provides contract manufacturing of various dosage forms, such as tablets, capsules, liquid injections, lyophilized injectables, and sterile dry powder injectables. It is also involved in the wind power generation activities. Shilpa Medicare Limited was incorporated in 1987 and is headquartered in Raichur, India.
Technical Analysis
Alkem Laboratories Ltd.
―
Dr. Reddy's Laboratories Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
Sanofi India Limited
―